Skip to main content
Premium Trial:

Request an Annual Quote

NIAMS to Fund Small Business Grants for Multiplex Assay Projects

NEW YORK (GenomeWeb News) – The National Institute of Arthritis and Musculoskeletal and Skin Diseases aims to fund small businesses developing new multiplex diagnostic technologies that target biomarkers for a range of diseases.

NIAMS plans to provide Small Business Innovation Research grants of $150,000 for phase I projects and $1 million for phase II efforts to businesses developing multiplex tools for measuring multiple protein, DNA, or RNA-based biomarkers that can be detected in small volumes of fluid or biopsies.

Many of the diseases in the NIAMS portfolio, such as osteoarthritis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and others, are chronic, complex, and progress very slowly. The slow development of these disorders may offer many circulating biomarkers that could be used in early diagnosis, but the biological resources to evaluate those markers are in short supply, according to NIAMS.

Single marker assays have been used for a variety of diseases but they offer limited benefits, and few have become useful for routine clinical practice, NIAMS stated in a request for applications this week.

The institute sees multiplex arrays that measure multiple protein and genetic biomarkers as more useful for screening for disease, assessing disease risk, severity, and prognosis, and potentially saving time, cost, and sample consumption. Many disorders may require a panel of biomarkers to characterize the stage or nature of a disease, so NIAMS sees a need for high-throughput multiplex assays that can produce accurate quantitative data.

Today, few assays for multiple biomarkers are available in the multiplex format and allow high throughput of a large number of specimens that are required for proof-of-concept studies, and most of those lack sensitivity and reproducibility and have high variability, the institute said.

NIAMS said this program will fund development of multiplex assay platforms that rise above those limitations, can quantify multiple biomarker candidates in small quantities of biospecimens, and can incorporate new candidate biomarkers as they become available.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.